Cathelicidin, most often discussed by its active fragment name LL-37, is one of five peptides the FDA has scheduled for a second Pharmacy Compounding Advisory Committee review, expected by February 2027. It's a naturally occurring part of the human immune system, which makes it a somewhat different case from lab-designed peptides like BPC-157 or CJC-1295, but the same evidence and regulatory gaps apply to it as a compounded or purchased product.
What It Is
LL-37 is the active peptide fragment cleaved from a larger precursor protein called hCAP-18, which is produced by immune cells (including neutrophils) and epithelial tissue throughout the body, notably skin, the respiratory tract, and the gut lining. It's part of the innate immune system, the body's fast, non-specific first line of defense against pathogens, and it's one of the best-studied members of a broader family of molecules called host-defense (or antimicrobial) peptides. Because it's endogenous, meaning your body already makes it, LL-37 is sometimes marketed as more "natural" than synthetic research peptides. That framing doesn't change the regulatory reality: a synthesized, injectable version of LL-37 sold as a research or wellness product is not the same, from a safety-evidence standpoint, as the LL-37 your own immune system produces at controlled, localized concentrations.
What the Research Shows
Laboratory and animal research on LL-37 spans several areas: direct antimicrobial activity against a range of bacteria, some antiviral and antifungal activity in vitro, a role in wound healing and tissue repair in animal models, and immunomodulatory effects, meaning it can influence how other immune cells behave, sometimes promoting inflammation and sometimes dampening it depending on concentration and context. Much of this work is mechanistic and preclinical, conducted in cell cultures or rodent models rather than in controlled human trials. There is genuine scientific interest in LL-37 as a potential template for new antimicrobial or wound-healing therapies, particularly given rising antibiotic resistance, but that interest has not yet translated into a completed human clinical trial establishing a safe and effective dose for any indication. Some of the same research also shows a double-edged quality: LL-37 has been implicated in inflammatory skin conditions like rosacea and psoriasis when present at abnormal levels, a reminder that "immune peptide" doesn't automatically mean "purely beneficial peptide."
Regulatory Status
LL-37 is not an FDA-approved drug for any indication. It currently sits on the FDA's Category 2 bulk drug substances list, meaning the agency has determined there are outstanding safety questions that make it inappropriate for compounding pharmacies to use in compounded prescriptions without further review. The scheduled 2027 PCAC meeting will formally evaluate whether that status should change, alongside GHK-Cu, Melanotan II, dihexa, and PEG-MGF, but no decision has been made, and even a favorable advisory vote would not, on its own, make LL-37 an approved medication or automatically legal to compound.
Safety Considerations
Because there is no completed human trial establishing a safety profile for injectable or systemically administered LL-37, there's no established side-effect profile, no standardized dose, and no long-term safety data. Products marketed as LL-37 online are typically labeled "research use only," meaning they are explicitly not intended for human use, and they come from an unregulated supply chain with no guarantee of purity or accurate labeling. The dual role researchers have found for LL-37, useful in some contexts, potentially pro-inflammatory in others, is also a reason for particular caution rather than less.
The Bottom Line
LL-37 is a legitimate and actively studied part of human immune biology, and the research interest in it as a therapeutic template is real. But being naturally occurring in the body does not substitute for human clinical trial data on a manufactured, injectable version of the peptide, and none currently exists. Its inclusion in the FDA's upcoming second advisory panel reflects ongoing regulatory scrutiny, not an endorsement, and anyone curious about it should talk to a licensed physician rather than relying on marketing claims from unregulated sellers.